Bachem Holding AG
BCHMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.82B
Close$
$-21.66
123.8% downside
Current Fair Value
123.8% downsideOvervalued by 123.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $6.82 Billion |
|---|---|
| Enterprise Value | $6.97 Billion |
| Annual dividend | $0.57 |
| Dividend yield | 1.09% |
| Earnings per Share | $1.98 |
| Beta | 0.81 |
| Outstanding Shares | 74,935,540 |
Return
| Return on Equity | 19.71% |
|---|---|
| Return on Assets | 12.16% |
| Return on Invested Capital | 16.78% |
Valuation & Multiples
| P/E Ratio | 41.63 |
|---|---|
| PEG | -18382.67 |
| Price to Sales | 5.06 |
| Price to Book Ratio | 4.79 |
| Enterprise Value to Revenue | 5.04 |
| Enterprise Value to EBIT | 22.94 |
| Enterprise Value to Net Income | 24 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.58
Consensus analyst estimateRevenue Estimate
$401.73 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$1.90
Consensus analyst estimateRevenue Estimate
$740.91 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Bachem Holding AG
2,511 employees
CEO: Anne-Kathrin Stoller
Bachem Holding AG provides essential products to pharmaceutical and biotechnology companies worldwide, supporting their activities from early research and clinical trials through to commercial manufacturing. The company's primary focus i...